Clinical trial

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT06710132

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention M9140 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2025-01-29

PhasePHASE1 / PHASE2

Conditions

Solid Tumorsunresolved

Gastric Cancerverified · MONDO: gastric cancer

Non-Small Cell Lung Cancer (NSCLC)unresolved

Pancreatic Cancerverified · MONDO: malignant pancreatic neoplasm

Pancreatic Ductal Adenocarcinoma (PDAC)unresolved

Interventions

M9140DRUG

Sponsors & collaborators

EMD Serono Research & Development Institute, Inc.lead sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germanycollaborator

Merck KGaA, Darmstadt, Germanycollaborator

Mapped research locations

SeoulSouth Korea5 MadridSpain4 BarcelonaSpain3 ParisFrance2 MilanItaly2 SevilleSpain2 LilleFrance2 ChengduSichuan, China2 HoustonTexas, United States1 BerlinGermany1 Washington D.C.District of Columbia, United States1 BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06710132 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.